Evidence map›Paper›PMID 38310425›Full record

Trial reportArchives of Iranian medicine2023

Safety and Effectiveness of Cinnomer

Abdorreza Naser Moghadasi, Fereshteh Ashtari, Seyed Mohammad Baghbanian, Vahid Shaygannejad, Nassim Anjidani, Fereshteh Ghadiri, Behnaz Sedighi, Morteza Saeidi, Hamed Amirifard, Hormoz Ayromlou and 7 more

Abstract readClinical Trial, Phase IVMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Archives of Iranian medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Abdorreza Naser MoghadasiMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-8598-0911
Fereshteh AshtariIsfahan University of Medical sciences, Kashani Comprehensive MS Center, Isfahan, Iran.
Seyed Mohammad BaghbanianMultiple Sclerosis Fellowship, Neurology Department, Boualicina Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
Vahid ShaygannejadIsfahan University of Medical sciences, Kashani Comprehensive MS Center, Isfahan, Iran.
Nassim AnjidaniMedical Department, Orchid Pharmed Company, Tehran, Iran.
Fereshteh GhadiriMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Behnaz SedighiNeurology Research Center, Kerman University of Medical Science, Kerman, Iran.
Morteza SaeidiDepartment of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamed AmirifardDepartment of Neurology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Hormoz AyromlouNeurology Department, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
Nahid Beladi MoghadamDepartment of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Bagher RanjbarPastour Building, Shiraz, Iran.
Masoume NazeriClinical Neurology Research Center, Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra NiknamKosar Hospital, Shiraz, Iran.
Fardin FarajiDepartment of Neurology, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Afsaneh AfsordeSina Building, Shiraz, Iran.
Mohammad Ali SahraianMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-3224-8807

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvery patient diagnosed with definite multiple sclerosis (MS) should begin disease modifying therapies. Cinnomer

methodsA phase IV multicenter study was conducted to explore the safety and effectiveness of Cinnomer

resultsTotally, 368 Iranian relapsing-remitting MS patients in nine cities were enrolled. The patients were either treatment naïve (n=191) or switchers (n=177). Cinnomer

conclusionSafety measures were in line with the known profiles of GA. The results suggest that Cinnomer

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingDepressionGlatiramer AcetateHumansIranProspective StudiesQuality of LifeGlatiramer AcetateCinnomer®Clinical trial phase IVGlatiramer acetateMultiple sclerosisQuality of life

Identifiers

PMID38310425
PMCPMC10864943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.